ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Recruiting
N/A
Interventional Study
Craniopharyngioma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 14 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Deling Li · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* must be able to provide a written informed consent
* radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
* adequate clinical condition (Karnofsky performance status ≥70)
Exclusion criteria:
* concomitant major central nervous sys…
Contacts